USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
AU560087B2
(en)
|
1981-09-08 |
1987-03-26 |
Rockefeller University, The |
Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
|
US4510245A
(en)
|
1982-11-18 |
1985-04-09 |
Chiron Corporation |
Adenovirus promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4704366A
(en)
|
1984-06-22 |
1987-11-03 |
Bio-Rad Laboratories, Inc. |
Process for binding IgG to protein A
|
US5672347A
(en)
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
DE3431140A1
(de)
|
1984-08-24 |
1986-03-06 |
Behringwerke Ag, 3550 Marburg |
Enhancer fuer eukaryotische expressionssysteme
|
IL73883A
(en)
|
1984-12-20 |
1990-12-23 |
Yeda Res & Dev |
Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
US5672502A
(en)
|
1985-06-28 |
1997-09-30 |
Celltech Therapeutics Limited |
Animal cell culture
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
EP0212489B1
(en)
|
1985-08-16 |
1994-11-30 |
The Rockefeller University |
Anabolic activity modulator and uses thereof
|
US4968615A
(en)
|
1985-12-18 |
1990-11-06 |
Ciba-Geigy Corporation |
Deoxyribonucleic acid segment from a virus
|
US5681718A
(en)
|
1986-03-14 |
1997-10-28 |
Celltech Limited |
Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
DE3631229A1
(de)
|
1986-09-13 |
1988-03-24 |
Basf Ag |
Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
US5045468A
(en)
|
1986-12-12 |
1991-09-03 |
Cell Enterprises, Inc. |
Protein-free culture medium which promotes hybridoma growth
|
US4877608A
(en)
|
1987-11-09 |
1989-10-31 |
Rorer Pharmaceutical Corporation |
Pharmaceutical plasma protein formulations in low ionic strength media
|
US5118796A
(en)
|
1987-12-09 |
1992-06-02 |
Centocor, Incorporated |
Efficient large-scale purification of immunoglobulins and derivatives
|
JP2638652B2
(ja)
|
1988-07-18 |
1997-08-06 |
カイロン・コーポレーション |
カケクチンと反応するモノクロナール抗体
|
US6048728A
(en)
|
1988-09-23 |
2000-04-11 |
Chiron Corporation |
Cell culture medium for enhanced cell growth, culture longevity, and product expression
|
DE68925971T2
(de)
|
1988-09-23 |
1996-09-05 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
US5126250A
(en)
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
DE68914244T2
(de)
|
1988-10-24 |
1994-10-27 |
Otsuka Pharma Co Ltd |
Monoklonaler Antikörper.
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US4933435A
(en)
|
1989-04-05 |
1990-06-12 |
Bioprobe International |
Antibody purification process
|
EP0486526B2
(en)
|
1989-08-07 |
2001-03-07 |
Peptech Limited |
Tumour necrosis factor binding ligands
|
US6448380B2
(en)
|
1989-08-07 |
2002-09-10 |
Peptech Limited |
Tumor necrosis factor antibodies
|
US5959087A
(en)
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5945098A
(en)
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
US5378612A
(en)
|
1990-05-11 |
1995-01-03 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Culture medium for production of recombinant protein
|
US5110913A
(en)
|
1990-05-25 |
1992-05-05 |
Miles Inc. |
Antibody purification method
|
US5096816A
(en)
|
1990-06-05 |
1992-03-17 |
Cetus Corporation |
In vitro management of ammonia's effect on glycosylation of cell products through pH control
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
GB9022547D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Purified immunoglobulin
|
GB9022545D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
US5994510A
(en)
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
GB2279077B
(en)
|
1990-12-21 |
1995-06-14 |
Celltech Ltd |
Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
|
GB9109645D0
(en)
|
1991-05-03 |
1991-06-26 |
Celltech Ltd |
Recombinant antibodies
|
GB9028123D0
(en)
|
1990-12-28 |
1991-02-13 |
Erba Carlo Spa |
Monoclonal antibodies against human tumor necrosis factor alpha
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
DK0610201T4
(da)
|
1991-03-18 |
2008-02-04 |
Centocor Inc |
Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US5698195A
(en)
|
1991-03-18 |
1997-12-16 |
New York University Medical Center |
Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
|
US20070298040A1
(en)
|
1991-03-18 |
2007-12-27 |
Centocor, Inc. |
Methods of treating seronegative arthropathy with anti-TNF antibodies
|
US20040120952A1
(en)
|
2000-08-07 |
2004-06-24 |
Centocor, Inc |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US5656272A
(en)
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
US20060246073A1
(en)
|
1991-03-18 |
2006-11-02 |
Knight David M |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US5328985A
(en)
|
1991-07-12 |
1994-07-12 |
The Regents Of The University Of California |
Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
|
ATE243747T1
(de)
|
1991-07-15 |
2003-07-15 |
Wellcome Found |
Herstellung von antikörpern
|
DK0605522T3
(da)
|
1991-09-23 |
2000-01-17 |
Medical Res Council |
Fremgangsmåde til fremstilling af humaniserede antistoffer
|
GB9122820D0
(en)
|
1991-10-28 |
1991-12-11 |
Wellcome Found |
Stabilised antibodies
|
ATE381614T1
(de)
|
1992-07-24 |
2008-01-15 |
Amgen Fremont Inc |
Bildung von xenogenen antikörpern
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
WO1994008619A1
(en)
|
1992-10-08 |
1994-04-28 |
The Kennedy Institute Of Rheumatology |
Treatment of autoimmune and inflammatory disorders
|
DK0614984T4
(da)
|
1993-03-05 |
2010-12-20 |
Bayer Healthcare Llc |
Humane monoklonale anti-TNF-alfa-antistoffer
|
CA2161351C
(en)
|
1993-04-26 |
2010-12-21 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
JPH08510642A
(ja)
|
1993-05-12 |
1996-11-12 |
ゾマ コーポレイション |
ゲロニンおよび抗体から成る免疫毒素
|
GB2294267B
(en)
|
1993-06-03 |
1996-11-20 |
Therapeutic Antibodies Inc |
Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
|
AU8083594A
(en)
|
1993-10-19 |
1995-05-08 |
Scripps Research Institute, The |
Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
|
EP0659766A1
(en)
|
1993-11-23 |
1995-06-28 |
Schering-Plough |
Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
|
EP0666312A1
(en)
|
1994-02-08 |
1995-08-09 |
Wolfgang A. Renner |
Process for the improvement of mammalian cell growth
|
US5429746A
(en)
|
1994-02-22 |
1995-07-04 |
Smith Kline Beecham Corporation |
Antibody purification
|
WO1995023813A1
(en)
|
1994-03-04 |
1995-09-08 |
Merck & Co., Inc. |
In vitro antibody affinity maturation using alanine scanning mutagenesis
|
US5856179A
(en)
|
1994-03-10 |
1999-01-05 |
Genentech, Inc. |
Polypeptide production in animal cell culture
|
NZ288997A
(en)
|
1994-06-24 |
1999-01-28 |
Immunex Corp |
Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate
|
ZA955642B
(en)
|
1994-07-07 |
1997-05-06 |
Ortho Pharma Corp |
Lyophilized imaging agent formulation
|
US5561053A
(en)
|
1994-08-05 |
1996-10-01 |
Genentech, Inc. |
Method for selecting high-expressing host cells
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
ES2304786T3
(es)
|
1995-04-27 |
2008-10-16 |
Amgen Fremont Inc. |
Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
US6656466B1
(en)
|
1995-06-06 |
2003-12-02 |
Genetech, Inc. |
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
|
US5721121A
(en)
|
1995-06-06 |
1998-02-24 |
Genentech, Inc. |
Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
JPH11510170A
(ja)
|
1995-07-27 |
1999-09-07 |
ジェネンテック インコーポレーテッド |
タンパク質の処方
|
JP4306813B2
(ja)
|
1995-09-19 |
2009-08-05 |
アスビオファーマ株式会社 |
動物細胞の新規培養方法
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
AR005035A1
(es)
|
1995-12-11 |
1999-04-07 |
Merck Patent Ges Mit Beschränkter Haftung |
Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
|
RU2270030C2
(ru)
|
1996-02-09 |
2006-02-20 |
Абботт Байотекнолоджи эЛтиди. |
СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ
|
PT802257E
(pt)
|
1996-04-19 |
2003-01-31 |
Nestle Sa |
Linhagem imortalizada de celulas epiteliais do colon humano
|
US20040171152A1
(en)
|
1996-10-10 |
2004-09-02 |
Invitrogen Corporation |
Animal cell culture media comprising non-animal or plant-derived nutrients
|
EP1864999B1
(en)
|
1996-11-27 |
2009-03-18 |
Genentech, Inc. |
Affinity purification of polypeptide on protein a matrix
|
DK1500329T3
(da)
|
1996-12-03 |
2012-07-09 |
Amgen Fremont Inc |
Humane antistoffer, der specifikt binder TNF-alfa
|
GB9625175D0
(en)
|
1996-12-04 |
1997-01-22 |
Medi Cult As |
Serum-free cell culture media
|
NZ337828A
(en)
|
1997-04-28 |
2001-06-29 |
Lilly Co Eli |
Activated protein C formulations having a bulking agent and a salt
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
EP0999853B1
(en)
|
1997-06-13 |
2003-01-02 |
Genentech, Inc. |
Stabilized antibody formulation
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US20020045207A1
(en)
|
1997-10-31 |
2002-04-18 |
Lynne A. Krummen |
Glycoprotein production process
|
WO1999032605A1
(en)
|
1997-12-19 |
1999-07-01 |
Novo Nordisk A/S |
Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
|
WO1999057246A1
(en)
|
1998-05-01 |
1999-11-11 |
Life Technologies, Inc. |
Animal cell culture media comprising non-animal or plant-derived nutrients
|
ATE321066T1
(de)
|
1998-05-06 |
2006-04-15 |
Genentech Inc |
Anti-her2 antikörperzusammensetzung
|
EP1308455B9
(en)
|
1998-05-06 |
2006-06-14 |
Genentech, Inc. |
A composition comprising anti-HER2 antibodies
|
DE19822031C2
(de)
|
1998-05-15 |
2000-03-23 |
Disetronic Licensing Ag |
Autoinjektionsgerät
|
DE19821933C1
(de)
|
1998-05-15 |
1999-11-11 |
Disetronic Licensing Ag |
Vorrichtung zur Verabreichung eines injizierbaren Produkts
|
US6528286B1
(en)
|
1998-05-29 |
2003-03-04 |
Genentech, Inc. |
Mammalian cell culture process for producing glycoproteins
|
US6406909B1
(en)
|
1998-07-10 |
2002-06-18 |
Chugai Seiyaku Kabushiki Kaisha |
Serum-free medium for culturing animal cells
|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
AU3633000A
(en)
|
1999-03-26 |
2000-10-16 |
Human Genome Sciences, Inc. |
Neutrokine-alpha binding proteins and methods based thereon
|
WO2000066160A1
(fr)
|
1999-04-28 |
2000-11-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
|
AU778022B2
(en)
|
1999-07-30 |
2004-11-11 |
Genentech Inc. |
Charged filtration membranes and uses therefor
|
JP2003510087A
(ja)
|
1999-09-27 |
2003-03-18 |
ジェネンテック・インコーポレーテッド |
アポトーシス阻害剤を用いた組換えタンパク質の作成方法
|
AR026743A1
(es)
|
1999-12-09 |
2003-02-26 |
Pharmacia Ab |
Produccion de peptidos
|
KR20010056451A
(ko)
|
1999-12-15 |
2001-07-04 |
윤재승 |
아르기닌이 강화된 동물세포 배양용 배지 조성물
|
AU2228901A
(en)
|
1999-12-28 |
2001-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Stable antibody compositions and injection preparations
|
CA2399266A1
(en)
|
2000-02-08 |
2001-08-16 |
Genentech, Inc. |
Improved galactosylation of recombinant glycoproteins
|
TWI373343B
(en)
|
2000-02-10 |
2012-10-01 |
Abbott Gmbh & Co Kg |
Antibodies that bind human interleukin-18 and methods of making and using
|
GB0003231D0
(en)
|
2000-02-11 |
2000-04-05 |
Medi Cult As |
Cell culture media
|
AU2001246846A1
(en)
|
2000-04-06 |
2001-10-23 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoassay of anti-hm1.24 antibody
|
EP1276849A4
(en)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US7598055B2
(en)
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
JP5490972B2
(ja)
|
2000-08-04 |
2014-05-14 |
中外製薬株式会社 |
タンパク質注射製剤
|
US20060018907A1
(en)
|
2000-08-07 |
2006-01-26 |
Centocor, Inc. |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US20050249735A1
(en)
|
2000-08-07 |
2005-11-10 |
Centocor, Inc. |
Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6635448B2
(en)
|
2000-08-21 |
2003-10-21 |
Clonexdevelopment, Inc. |
Methods and compositions for increasing protein yield from a cell culture
|
WO2002066603A2
(en)
|
2001-02-15 |
2002-08-29 |
Centocor, Inc. |
Chemically defined medium for cultured mammalian cells
|
US20030096414A1
(en)
|
2001-03-27 |
2003-05-22 |
Invitrogen Corporation |
Culture medium for cell growth and transfection
|
CA2446734A1
(en)
|
2001-05-24 |
2002-11-28 |
Human Genome Sciences, Inc. |
Antibodies against tumor necrosis factor delta (april)
|
US20030012786A1
(en)
|
2001-05-25 |
2003-01-16 |
Teoh Leah S. |
Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
PL222211B1
(pl)
|
2001-06-26 |
2016-07-29 |
Amgen Fremont Inc |
Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
|
NZ592087A
(en)
|
2001-08-03 |
2012-11-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
GB0119520D0
(en)
|
2001-08-10 |
2001-10-03 |
Owen Mumford Ltd |
Improvements relating to injection devices
|
CA2460206C
(en)
|
2001-10-02 |
2012-01-24 |
Novo Nordisk Health Care Ag |
Method for production of recombinant proteins in eukaryote cells
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
AU2002340787B2
(en)
|
2001-11-12 |
2009-09-17 |
Monash University |
Peptide purification by means of metal ion affinity chromatography
|
PL368749A1
(en)
|
2001-11-28 |
2005-04-04 |
Sandoz Ag |
Cell culture process
|
WO2003059935A2
(en)
|
2001-12-21 |
2003-07-24 |
Immunex Corporation |
Methods for purifying protein
|
AU2003210802B2
(en)
|
2002-02-05 |
2009-09-10 |
Genentech Inc. |
Protein purification
|
US20030161828A1
(en)
|
2002-02-19 |
2003-08-28 |
Abbott Gmbh & Co. Kg |
Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
|
CA2417689C
(en)
|
2002-03-05 |
2006-05-09 |
F. Hoffmann-La Roche Ag |
Improved methods for growing mammalian cells in vitro
|
JP2005521401A
(ja)
|
2002-03-27 |
2005-07-21 |
イミュネックス・コーポレーション |
ポリペプチド産生を増加させる方法
|
US20030190710A1
(en)
|
2002-03-28 |
2003-10-09 |
Devries Ruth L. |
Control of glycoforms in IgG
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
CA2478925C
(en)
|
2002-04-26 |
2016-06-07 |
Robert Lee Fahrner |
Non-affinity purification of proteins
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20040009172A1
(en)
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20040029229A1
(en)
|
2002-05-20 |
2004-02-12 |
Reeves Philip J. |
High level protein expression system
|
MXPA05000552A
(es)
|
2002-07-15 |
2005-04-28 |
Immunex Corp |
Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
|
US20090280065A1
(en)
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
AU2003267999B2
(en)
|
2002-07-19 |
2010-03-11 |
Abbvie Biotechnology Ltd |
Treatment of TNFalpha related disorders
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US6974681B1
(en)
|
2002-08-23 |
2005-12-13 |
Immunex Corporation |
Cell culture performance with vanadate
|
US6924124B1
(en)
|
2002-08-23 |
2005-08-02 |
Immunex Corporation |
Feeding strategies for cell culture
|
US7067279B1
(en)
|
2002-08-23 |
2006-06-27 |
Immunex Corporation |
Cell culture performance with betaine
|
US6890736B1
(en)
|
2002-09-20 |
2005-05-10 |
Immunex Corporation |
Methods for producing proteins in cultured cells
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7674885B2
(en)
|
2002-11-01 |
2010-03-09 |
Bayer Healthcare Llc |
Process for concentration of macromolecules
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
US20040101939A1
(en)
|
2002-11-22 |
2004-05-27 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
US20040162414A1
(en)
|
2002-11-22 |
2004-08-19 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
CA2511520A1
(en)
|
2002-12-23 |
2004-07-15 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
CA2508925C
(en)
|
2002-12-23 |
2012-08-28 |
Bristol-Myers Squibb Company |
Product quality enhancement in mammalian cell culture processes for protein production
|
DK1620549T3
(da)
|
2003-05-01 |
2007-11-05 |
Dsm Ip Assets Bv |
Fremgangsmåde til fremstilling af biologiske stoffer ved perfusionsdyrkning af suspenderede dyreceller
|
ATE472597T2
(de)
|
2003-05-15 |
2010-07-15 |
Wyeth Llc |
Kontrollierte glukosezufuhr für tierzellkultur
|
GB2404665B
(en)
|
2003-08-08 |
2005-07-06 |
Cambridge Antibody Tech |
Cell culture
|
WO2005035748A1
(en)
|
2003-10-10 |
2005-04-21 |
Novo Nordisk Health Care Ag |
Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor
|
ES2342539T3
(es)
|
2003-10-24 |
2010-07-08 |
Amgen, Inc. |
Proceso para la purificacion de proteinas en una fraccion de flujo-directo de cromatografia de interaccion hidrofobica.
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
DE10355251A1
(de)
|
2003-11-26 |
2005-06-23 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
|
RU2390353C2
(ru)
|
2004-02-12 |
2010-05-27 |
Мерк Патент Гмбх |
Высококонцентрированные жидкие композиции анти-egfr антител
|
CA2552639C
(en)
|
2004-02-27 |
2012-05-01 |
Ge Healthcare Bio-Sciences Ab |
A process for the purification of antibodies
|
CN1234725C
(zh)
|
2004-04-07 |
2006-01-04 |
陈志南 |
一种高效快速纯化制备片段抗体的方法
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
US20060127950A1
(en)
|
2004-04-15 |
2006-06-15 |
Massachusetts Institute Of Technology |
Methods and products related to the improved analysis of carbohydrates
|
ATE455861T1
(de)
|
2004-05-04 |
2010-02-15 |
Novo Nordisk Healthcare Ag |
O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
DK1807101T3
(en)
|
2004-09-30 |
2016-05-23 |
Bayer Healthcare Llc |
Devices and methods for integrated continuous production of biological molecules
|
WO2006041970A2
(en)
|
2004-10-08 |
2006-04-20 |
Abbott Biotechnology Ltd. |
Treatment of respiratory syncytial virus (rsv) infection
|
WO2007011390A2
(en)
|
2004-10-09 |
2007-01-25 |
Government Of The United States As Represented By The Secretary Of The Army |
Large-scale production of human serum butyrylcholinesterase as a bioscavenger
|
JP4831436B2
(ja)
|
2004-10-21 |
2011-12-07 |
ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ |
クロマトグラフィーリガンド
|
US20060094104A1
(en)
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
JP2008529495A
(ja)
|
2005-02-04 |
2008-08-07 |
グラクソ グループ リミテッド |
異種ポリペプチド発現の最適化
|
WO2006084826A1
(en)
|
2005-02-11 |
2006-08-17 |
Novo Nordisk Health Care Ag |
Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
|
MX2007011129A
(es)
|
2005-03-11 |
2007-11-06 |
Wyeth Corp |
Un metodo de cromatografia de particion debil.
|
WO2006107990A2
(en)
|
2005-04-05 |
2006-10-12 |
The Johns Hopkins University |
Improving protein n-glycosylation of eukaryotic cells using dolichol-linked oligosaccharide synthesis pathway, other n-gylosylation-increasing methods, and engineered hosts expressing products with increased n-glycosylation
|
MX2007012499A
(es)
|
2005-04-11 |
2007-12-06 |
Medarex Inc |
Purificacion de proteinas.
|
US20090203055A1
(en)
|
2005-04-18 |
2009-08-13 |
Massachusetts Institute Of Technology |
Compositions and methods for RNA interference with sialidase expression and uses thereof
|
US8349991B2
(en)
|
2005-04-19 |
2013-01-08 |
Massachusetts Institute Of Technology |
Amphiphilic polymers and methods of use thereof
|
NZ591701A
(en)
|
2005-05-16 |
2012-11-30 |
Abbott Biotech Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
WO2006133148A2
(en)
|
2005-06-03 |
2006-12-14 |
Genentech, Inc. |
Method of producing antibodies with modified fucosylation level
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
LT1917276T
(lt)
|
2005-08-26 |
2018-05-25 |
Ares Trading S.A. |
Glikozilinto interferono beta gavimo būdas
|
PE20070796A1
(es)
|
2005-10-24 |
2007-08-15 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
EP1948235B1
(en)
|
2005-11-01 |
2013-08-28 |
AbbVie Biotechnology Ltd |
Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers
|
ES2564790T5
(es)
|
2005-12-08 |
2023-08-25 |
Amgen Inc |
Producción mejorada de glicoproteínas usando manganeso
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
US20070202051A1
(en)
|
2006-02-10 |
2007-08-30 |
Pari Gmbh |
Aerosols for sinunasal drug delivery
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
US20080118496A1
(en)
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
WO2007120656A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of rheumatoid arthritis
|
EP2012586A4
(en)
|
2006-04-10 |
2010-08-18 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
|
US20090317399A1
(en)
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US9624295B2
(en)
|
2006-04-10 |
2017-04-18 |
Abbvie Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
US20080131374A1
(en)
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
EP2032600A2
(en)
|
2006-05-19 |
2009-03-11 |
Glycofi, Inc. |
Erythropoietin compositions
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
TWI498137B
(zh)
|
2006-06-30 |
2015-09-01 |
Abbvie Biotechnology Ltd |
自動注射裝置
|
DK2041270T3
(da)
|
2006-07-13 |
2014-01-27 |
Wyeth Llc |
Fremstilling af glycoproteiner
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
AU2007294731B2
(en)
|
2006-09-13 |
2014-04-17 |
Abbvie Inc. |
Cell culture improvements
|
US10982250B2
(en)
|
2006-09-18 |
2021-04-20 |
Genentech, Inc. |
Methods of protein production
|
EP2081553B1
(en)
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
BRPI0717335A2
(pt)
|
2006-10-27 |
2013-12-10 |
Abbott Biotech Ltd |
Anticorpos anti-htnfalfa cristalinos
|
MX2009004519A
(es)
|
2006-11-03 |
2009-05-12 |
Wyeth Corp |
Sustancias que inhiben la glucolisis en un cultivo de celulas.
|
US20110105734A1
(en)
|
2006-12-06 |
2011-05-05 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human erythropoietin
|
JP2010516651A
(ja)
|
2007-01-17 |
2010-05-20 |
メルク セローノ ソシエテ アノニム |
Fc含有タンパク質の精製のための方法
|
KR20090127326A
(ko)
|
2007-03-02 |
2009-12-10 |
와이어쓰 |
폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
|
NZ598881A
(en)
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
WO2008120107A2
(en)
|
2007-04-03 |
2008-10-09 |
Oxyrane (Uk) Limited |
Glycosylation of molecules
|
CA2682738A1
(en)
|
2007-04-16 |
2008-10-23 |
Momenta Pharmaceuticals, Inc. |
Defined glycoprotein products and related methods
|
TW200902708A
(en)
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
WO2008135498A2
(en)
|
2007-05-04 |
2008-11-13 |
Novo Nordisk A/S |
Prevention of protein degradation in mammalian cell cultures
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
AU2008251405B2
(en)
|
2007-05-11 |
2012-05-17 |
Amgen Inc. |
Improved feed media
|
EP2679996A1
(en)
|
2007-05-31 |
2014-01-01 |
AbbVie Inc. |
Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
|
WO2008150490A2
(en)
|
2007-06-01 |
2008-12-11 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriasis and crohn's disease
|
US20100221823A1
(en)
|
2007-06-11 |
2010-09-02 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
SI3597659T1
(sl)
|
2007-07-09 |
2023-04-28 |
Genentech, Inc. |
Preprečevanje redukcije disulfidne vezi med rekombinantno proizvodnjo polipeptidov
|
WO2009011782A2
(en)
|
2007-07-13 |
2009-01-22 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
|
US8753839B2
(en)
|
2007-08-08 |
2014-06-17 |
Abbvie Inc. |
Compositions and methods for crystallizing antibodies
|
WO2009023562A2
(en)
|
2007-08-09 |
2009-02-19 |
Wyeth |
Use of perfusion to enhance production of fed-batch cell culture in bioreactors
|
MX2010002269A
(es)
|
2007-08-28 |
2010-03-25 |
Abbott Biotech Ltd |
Composiciones y metodos que comprenden proteinas de union para adalimumab.
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
CN101784670A
(zh)
|
2007-08-31 |
2010-07-21 |
弗·哈夫曼-拉罗切有限公司 |
糖基化谱分析
|
WO2009058769A1
(en)
|
2007-10-30 |
2009-05-07 |
Schering Corporation |
Purification of antibodies containing hydrophobic variants
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
CA2707483A1
(en)
|
2007-11-30 |
2009-06-11 |
Wolfgang Fraunhofer |
Protein formulations and methods of making same
|
US20130195888A1
(en)
|
2007-11-30 |
2013-08-01 |
Abbvie |
Ultrafiltration and diafiltration formulation methods for protein processing
|
ES2644089T3
(es)
|
2007-12-27 |
2017-11-27 |
Baxalta GmbH |
Procedimientos de cultivo celular
|
WO2009086550A1
(en)
|
2008-01-03 |
2009-07-09 |
Abbott Laboratories |
Predicting long-term efficacy of a compound in the treatment of psoriasis
|
EP2784089A1
(en)
|
2008-01-15 |
2014-10-01 |
AbbVie Inc. |
Improved mammalian expression vectors and uses thereof
|
MX2010007728A
(es)
|
2008-01-15 |
2010-12-21 |
Abbott Gmbh & Co Kg |
Composiciones proteinicas en polvo y metodos para elaborar las mismas.
|
CA2713342A1
(en)
|
2008-01-30 |
2009-08-13 |
Abbott Laboratories |
Compositions and methods for crystallizing antibody fragments
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
CA2717614A1
(en)
|
2008-03-11 |
2009-09-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
MX2010010503A
(es)
|
2008-03-24 |
2010-11-09 |
Abbott Biotech Ltd |
Metodos y composiciones para tratar perdida osea.
|
ES2458541T3
(es)
|
2008-05-02 |
2014-05-06 |
Seattle Genetics, Inc. |
Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
|
WO2009135656A1
(en)
|
2008-05-06 |
2009-11-12 |
Lonza Biologics Plc. |
A method for the purification of antibodies using displacement chromatography
|
US8318416B2
(en)
|
2008-08-08 |
2012-11-27 |
Biogen Idec Ma Inc. |
Nutrient monitoring and feedback control for increased bioproduct production
|
KR20110084196A
(ko)
|
2008-09-26 |
2011-07-21 |
유레카 쎄라퓨틱스, 인코포레이티드 |
다양한 글리코실화 패턴을 가진 세포계 및 단백질
|
WO2010043703A1
(en)
|
2008-10-17 |
2010-04-22 |
Dsm Ip Assets B.V. |
Removal of host cell proteins
|
CA2932207A1
(en)
|
2008-10-20 |
2010-12-09 |
Abbvie Inc. |
Isolation and purification of antibodies using protein a affinity chromatography
|
JP5856845B2
(ja)
|
2008-10-20 |
2016-02-10 |
アッヴィ・インコーポレイテッド |
抗体精製中におけるウイルスの不活性化
|
BRPI1015019A2
(pt)
|
2009-04-20 |
2018-02-14 |
Pfizer |
controle de glicosilação de proteína e composições e métodos relacionada a ele.
|
JP5677411B2
(ja)
|
2009-04-29 |
2015-02-25 |
アッヴィ バイオテクノロジー リミテッド |
自動注入機器
|
WO2010127069A1
(en)
|
2009-04-29 |
2010-11-04 |
Schering Corporation |
Antibody purification
|
RU2560701C2
(ru)
|
2009-05-04 |
2015-08-20 |
Эббви Байотекнолоджи Лтд. |
Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
|
KR20120042744A
(ko)
|
2009-05-28 |
2012-05-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
합리적인 세포 배양 공정을 위한 방법
|
EP2438185A4
(en)
|
2009-06-05 |
2016-10-05 |
Momenta Pharmaceuticals Inc |
METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS
|
CN102482633A
(zh)
|
2009-07-06 |
2012-05-30 |
弗·哈夫曼-拉罗切有限公司 |
真核细胞的培养方法
|
CA2768325C
(en)
|
2009-07-24 |
2019-10-29 |
F. Hoffmann-La Roche Ag |
Optimizing the production of antibodies
|
US8945895B2
(en)
|
2009-07-31 |
2015-02-03 |
Baxter International Inc. |
Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
|
WO2011015926A1
(en)
|
2009-08-03 |
2011-02-10 |
Avesthagen Limited |
A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
|
HUE048980T2
(hu)
|
2009-08-11 |
2020-08-28 |
Hoffmann La Roche |
Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban
|
US20110053223A1
(en)
|
2009-08-14 |
2011-03-03 |
Robert Bayer |
Cell culture methods to make antibodies with enhanced adcc function
|
WO2011024025A1
(en)
|
2009-08-28 |
2011-03-03 |
Avesthagen Limited |
An erythropoietin analogue and a method thereof
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
US8470552B2
(en)
|
2009-10-12 |
2013-06-25 |
Keck Graduate Institute |
Strategy to reduce lactic acid production and control PH in animal cell culture
|
US9096879B2
(en)
|
2009-11-24 |
2015-08-04 |
Biogen Ma Inc. |
Method of supplementing culture media to prevent undesirable amino acid substitutions
|
EP2507627A2
(en)
|
2009-12-04 |
2012-10-10 |
Momenta Pharmaceuticals, Inc. |
Antennary fucosylation in glycoproteins from cho cells
|
PL3715356T3
(pl)
|
2009-12-18 |
2024-03-11 |
Csl Limited |
Sposób oczyszczania polipeptydów
|
US20120014956A1
(en)
|
2010-02-02 |
2012-01-19 |
Hartmut Kupper |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
KR20120118065A
(ko)
|
2010-02-12 |
2012-10-25 |
디에스엠 아이피 어셋츠 비.브이. |
단일 단위체 항체 정제
|
KR101555740B1
(ko)
|
2010-03-10 |
2015-09-25 |
에프. 호프만-라 로슈 아게 |
면역글로불린 용액 정제 방법
|
BR112012025645A2
(pt)
|
2010-04-07 |
2017-12-12 |
Momenta Pharmaceuticals Inc |
glicanos de alta manose.
|
ES2617777T5
(es)
|
2010-04-23 |
2022-10-13 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas
|
WO2011134920A1
(en)
|
2010-04-26 |
2011-11-03 |
Novartis Ag |
Improved cell culture medium
|
LT2563906T
(lt)
|
2010-04-26 |
2018-02-26 |
Novartis Ag |
Cho ląstelių kultivavimo būdas
|
JP6050226B2
(ja)
|
2010-05-28 |
2016-12-21 |
ジェネンテック, インコーポレイテッド |
Ldh及びpdhk発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
|
US8747854B2
(en)
|
2010-06-03 |
2014-06-10 |
Abbvie Biotechnology Ltd. |
Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
|
CN103080300B
(zh)
|
2010-08-05 |
2015-11-25 |
安姆根有限公司 |
增加细胞培养物的产率和活力的二肽
|
DE102010038990A1
(de)
|
2010-08-06 |
2012-02-09 |
Robert Bosch Gmbh |
Wellenlagervorrichtung für eine Handwerkzeugmaschine
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
WO2012037430A1
(en)
|
2010-09-17 |
2012-03-22 |
Abbott Laboratories |
Raman spectroscopy for bioprocess operations
|
KR20130142128A
(ko)
|
2010-10-11 |
2013-12-27 |
애브비 인코포레이티드 |
단백질의 정제 방법
|
CN103154243A
(zh)
|
2010-10-15 |
2013-06-12 |
日本化学研究株式会社 |
糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
|
EP2450375A1
(en)
|
2010-11-09 |
2012-05-09 |
Sandoz Gmbh |
Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
|
CA2815689C
(en)
|
2010-11-11 |
2016-11-22 |
Abbvie Biotechnology Ltd. |
Improved high concentration anti-tnf.alpha. antibody liquid formulations
|
AU2012204237A1
(en)
|
2011-01-07 |
2013-07-04 |
Abbvie Inc. |
Anti-IL-12/IL-23 antibodies and uses thereof
|
AU2012226398B9
(en)
|
2011-03-06 |
2017-04-13 |
Merck Serono S.A. |
Low fucose cell lines and uses thereof
|
WO2012125735A1
(en)
|
2011-03-15 |
2012-09-20 |
Abott Laboratories |
An integrated approach to the isolation and purification of antibodies
|
EP2511293A1
(en)
|
2011-04-13 |
2012-10-17 |
LEK Pharmaceuticals d.d. |
A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
|
WO2012145682A1
(en)
|
2011-04-21 |
2012-10-26 |
Amgen Inc. |
A method for culturing mammalian cells to improve recombinant protein production
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
US9670519B2
(en)
|
2011-04-29 |
2017-06-06 |
Biocon Limited |
Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
|
KR101591671B1
(ko)
|
2011-04-29 |
2016-02-04 |
바이오콘 리서치 리미티드 |
항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
|
US9562252B2
(en)
|
2011-05-13 |
2017-02-07 |
Biogen Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
WO2013006461A1
(en)
|
2011-07-01 |
2013-01-10 |
Biogen Idec Ma Inc. |
Cholesterol-based media supplementals for cell culture
|
KR102108663B1
(ko)
|
2011-07-01 |
2020-05-07 |
암젠 인크 |
포유동물 세포 배양
|
US9475858B2
(en)
|
2011-07-08 |
2016-10-25 |
Momenta Pharmaceuticals, Inc. |
Cell culture process
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
WO2013013013A2
(en)
|
2011-07-21 |
2013-01-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for producing modified glycoproteins
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013177115A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
|
US20140154270A1
(en)
|
2012-05-21 |
2014-06-05 |
Chen Wang |
Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
WO2013181585A2
(en)
|
2012-06-01 |
2013-12-05 |
Momenta Pharmaceuticals, Inc. |
Methods related to adalimumab
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US20140271633A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Mammalian cell culture performance through surfactant supplementation of feed media
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|